Follow

Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade

02 September 2020 - 15:00

Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade

Nanoform Finland Plc – Manager’s transactions – September 2, 2020 at 03:00 p.m. Finnish time

Manager’s transaction related to Nanoform Finland Plc’s other senior manager Goncalo Andrade’s share subscription with stock options from option program 2/2019.

Nanoform Finland Plc - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Goncalo Andrade

Position: Other senior manager

Issuer: Nanoform Finland Plc

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 743700JJO2NU8LBS1592_20200830183117_2

____________________________________________

Transaction date: 2020-08-29

Venue not applicable

Instrument type: SHARE

ISIN: FI4000330972

Nature of the transaction: EXERCISE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 10,000 Unit price: 1.1 EUR

Aggregated transactions

(1): Volume: 10,000 Volume weighted average price: 1.1 EUR

For further information, please contact:

Peter Hänninen, General Counsel

peter.hanninen@nanoform.com / +358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com / +46 7686 650 11

Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. The Company’s patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications. Nanoform’s share is listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS)

For more information please visit http://www.nanoform.com

Provided by: Cision
Nasdaq First North GM (Sweden)
Nanoform Finland Oyj
Nanoform Finland PLC is an nanoparticle medicine enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nanoforming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nanoformed API particles as small as 10nm. Thi...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date